RB-120

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
RB-120
RB120 Mesylate.png
Identifiers
  • N-{(S)-2-benzyl-3[(S)-(2-amino-4-methylthio)butyldithio]-1-oxopropyl}-l-alanine benzyl ester
PubChem CID
Chemical and physical data
FormulaC25H34N2O3S3
Molar mass506.74 g·mol−1
3D model (JSmol)
  • C[C@@H](C(=O)OCC1=CC=CC=C1)NC(=O)[C@H](CC2=CC=CC=C2)CSSC[C@H](CCSC)N
  • InChI=1S/C25H34N2O3S3/c1-19(25(29)30-16-21-11-7-4-8-12-21)27-24(28)22(15-20-9-5-3-6-10-20)17-32-33-18-23(26)13-14-31-2/h3-12,19,22-23H,13-18,26H2,1-2H3,(H,27,28)/t19-,22+,23-/m0/s1
  • Key:XHWYFTNNIZGHRW-PMOQBDJRSA-N

RB-120 (benzyl (2S)-2-{[(2S)-2-({[(2S)-2-amino-4-methylsulfanylbutyl]disulfanyl}methyl)-3-phenylpropanoyl]amino}propanoate) is an orally active analog of the drug RB-101.[1] It acts as an enkephalinase inhibitor, which is used in scientific research. Via intravenous administration, it is approximately three times as potent as RB-101 or twice as potent as the isolated (S,S) isomer of RB101. However, via i.p. administration it is approximately twice as potent as racemic RB-101 and about as potent as the isolated (S,S) isomer of RB101. During i.v. administration RB120 is approximately twice as weak as morphine in terms of analgesia, however it is 16x weaker during i.p. and p.o. administration.[1]

Dosage[edit]

RB 120 produces a significant dose-dependent antinociceptive response in the rat tail-flick test at 10 and 25 min after i.v. administration, at doses of 12.5, 25 and 50 mg/kg.[1] (equivalent to 2.0, 4.0, and 8.1 mg/kg in humans).[2]

The analgesic effect occurred with a slower onset compared to typical IV opioids likely due to the fact that, following enkephalinase inhibition, it may take some time for endogenous enkephalin to accumulate without degradation until sufficient concentration is reached for analgesic effect, whereas for opioids, onset only requires entry into the brain via the blood-brain barrier which occurs rapidly for lipophilic molecules, and binding to the opioid receptor produces a near-instantaneous G-protein mediated response and production of second messenger, without need for de novo synthesis of any neurotransmitters.

References[edit]

  1. ^ a b c Noble F, Smadja C, Valverde O, Maldonado R, Coric P, Turcaud S, et al. (December 1997). "Pain-suppressive effects on various nociceptive stimuli (thermal, chemical, electrical and inflammatory) of the first orally active enkephalin-metabolizing enzyme inhibitor RB 120". Pain. 73 (3): 383–91. doi:10.1016/S0304-3959(97)00125-5. PMID 9469529. S2CID 35842551.
  2. ^ Nair AB, Jacob S (March 2016). "A simple practice guide for dose conversion between animals and human". Journal of Basic and Clinical Pharmacy. 7 (2): 27–31. doi:10.4103/0976-0105.177703. PMC 4804402. PMID 27057123.